Penumbra Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Penumbra Inc's ROA in the second quarter of 2026?
Penumbra Inc achieved a return on average assets (ROA) of 8.63 % in its second quarter of 2026, this is above PEN's average return on assets of 3.41%.
Penumbra Inc assets over the 12 months ending in its second quarter of 2026 are valued at $1,861 million

ROA fell compared to the first quarter of 2026, despite the net income growth of 6.83% from the first quarter of 2026.

However, within the Healthcare sector 108 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 631, from total ROA ranking in the first quarter of 2026 at 666.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	17.91 %	19.15 %	34.49 %	33.98 %	23.74 %
Y / Y Net Income Change	-23.1 %	-16.93 %	40.55 %	55.28 %	-
Net Income (TTM) in million	161	171	178	164	148
Return On Assets (TTM)	8.63 %	9.58 %	10.39 %	10.3 %	9.97 %
PEN's Total Ranking	# 631	# 666	# 610	# 664	# 1651
Total Assets (TTM) in million	1,975	1,898	1,827	1,744	1,675
Seq. Total Assets Change	4.02 %	3.94 %	4.71 %	4.15 %	5.12 %
Seq. Net Income Change	6.83 %	-31.17 %	3.25 %	1.28 %	15.42 %

PEN's 5 Years Annual ROA >> Back to PEN Management Effectiveness >> Compare PEN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 32
Sector	# 109
Overall	# 712

Return On Assets Statistics
High	Average	Low
10.96 %	3.41 %	-2.5 %
(Dec 31 2016)		(Dec 31 2020)

Financial Statements
Penumbra Inc's Assets	$ 1,975 million	PEN's Balance sheet
Penumbra Inc's Income	$ 35 million	Quarterly PEN's Income Statement
PEN's Income by Division		See PEN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	34.49 %	-0.83 %	16.16 %	5.7 %	42.47 %
Total Assets in million	1,827	1,358	1,369	1,179	1,115
Y / Y Net Income Change	1168.11 %	-84.59 %	-	-	-
Net Income in million	178	14	91	-2	3
Annual Return On Assets	9.73 %	1.03 %	6.64 %	-0.17 %	0.24 %

PEN's 5 Years Annual ROA >> Back to PEN Management Effectiveness >> Compare PEN ROA to its Competitors

Comment on PEN's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 9.73 % compared to prior year, due to annual net income growth of 1168.11 % to $177.69 million, while value of Penumbra Inc's overall assets grew just by 34.49 % to $1,826.52 million, compared to $1,826.52 a year before.

More Return On Assets Ratios
PEN's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PEN's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PEN's Competitors
Subscribers only: Roa for Penumbra Inc's Suppliers
Subscribers only: Return On Assets for PEN's Customers

You may also want to know
PEN's Roi	PEN's Inventory Turnover Ratio	PEN's Growth Rates	PEN's Dividend Comparisons
	PEN's Profitability Ratios	PEN's Asset Turnover Ratio	PEN's Dividend Growth
PEN's Roe	PEN's Valuation Ratios	PEN's Financial Strength Ratios	PEN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %

Date modified: 2026-09-14T03:59:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.